Trial reportLeukemia2021
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.Bone marrow transplantation · 2025Guideline
- Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Pooled it
- Trial
- Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.Journal of patient-reported outcomes · 2024Trial
- Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.European journal of haematology · 2022Trial
- Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma.Bone marrow transplantation · 2026Article
- Article
- Is Salvage Autologous Stem Cell Transplantation Still a Viable Treatment Option in Relapsed Myeloma Patients?Medicina (Kaunas, Lithuania) · 2025Article
- Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?Annals of hematology · 2025Article
- Current Treatment Strategies for Multiple Myeloma at First Relapse.Journal of clinical medicine · 2025Review
- Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2025Observational
- Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life study.HemaSphere · 2024Article
- Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany.Bone marrow transplantation · 2024Article
- Observational
- Multiple Myeloma in 2023 Ways: From Trials to Real Life.Current oncology (Toronto, Ont.) · 2023Review
- Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.Bone marrow transplantation · 2023Article
- Review
- Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03).Clinical hematology international · 2023Article
- [Guidelines for the diagnosis and management of first relapsed multiple myeloma in China (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.Blood cancer journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 18 institutions in 2 countries.
Hartmut Goldschmidt *Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-0961-0035
Marc-Andrea Baertsch *Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4000-6904
Jana SchlenzkaDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Natalia BeckerDivision of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Christina HabermehlDivision of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Thomas HielscherDivision of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Marc-Steffen RaabDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Jens HillengassDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Sandra SauerDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Carsten Müller-TidowDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7166-5232
Steffen LuntzCoordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany.
Anna JauchInstitute for Human Genetics, University of Heidelberg, Heidelberg, Germany.
Dirk HoseDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Anja SeckingerDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Peter BrossartDepartment of Oncology, Hematology, Immuno-Oncology and Rheumatology, Med. Klinik und Poliklinik III, University Hospital Bonn, Bonn, Germany.
Martin GoernerDepartment of Hematology, Oncology and Palliative Care, Community Hospital Bielefeld, Bielefeld, Germany.
Stefan KleinDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
Martin Schmidt-HieberClinic for Hematology and Stem Cell Transplantation, Helios-Hospital Berlin Buch, Berlin, Germany.
Peter ReimerDepartment of Hematology, Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany.
Ullrich GraevenDepartment of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
Roland FenkDepartment of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany.
Mathias HaenelDepartment of Hematology, Oncology and Stem Cell Transplantation, Klinikum Chemnitz GmbH, Chemnitz, Germany.
Hans MartinDepartment of Hematology and Oncology, Goethe University, Frankfurt, Germany.
Hans W LindemannDepartment of Hematology and Oncology, Kath. Krankenhaus Hagen gem. GmbH, Hagen, Germany.
Christoph ScheidDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Axel NogaiInternal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany.
Hans SalwenderAsklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.
Richard NoppeneyDepartment of Hematology, University Hospital Essen, Essen, Germany.
Britta BesemerDepartment of Hematology, Oncology and Immunology, University of Tuebingen, Tuebingen, Germany.
Katja WeiselDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Myeloma Multicenter Group (GMMG)
Heidelberg University · DEGerman Cancer Research Center · DEAsklepios Klinik Altona · DECarl-Thiem-Klinikum Cottbus · DECharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEFernUniversität in Hagen · DEGoethe University Frankfurt · DEHeinrich Heine University Düsseldorf · DEKliniken Essen-Mitte · DEKliniken Maria Hilf · DEKlinikum Bielefeld · DEKlinikum Chemnitz · DERoswell Park Comprehensive Cancer Center · USUniversität Hamburg · DEUniversity Hospital Bonn · DEUniversity of Cologne · DEUniversity of Tübingen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m
Indexed as
Hematopoietic Stem Cell TransplantationAdolescentAdultAgedAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBiopsyBone MarrowChromosome AberrationsCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMiceBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.